Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
The goal of this study is to provide access to axicabtagene ciloleucel for patients diagnosed with a disease approved for treatment with axicabtagene ciloleucel, that is otherwise out of specification for commercial release.
Inclusion Criteria:
Exclusion Criteria:
medinfo@kitepharma.com844-454-5483(1-844-454-KITE)
St Louis, Missouri 63110, United States
Hackensack, New Jersey 07601, United States
New York, New York 10021, United States
Chapel Hill, North Carolina 27514, United States
Columbus, Ohio 43201, United States
San Antonio, Texas 782229, United States
Charlottesville, Virginia 22903, United States
Ehime, 791-0295, Japan
Gunma, 371-8511, Japan
Hokkaido, 003-0006, Japan
Hokkaido, 060-8648, Japan
Tokyo, 113-8677, Japan